SynthesisPloS one2011
Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis.
Synthesis in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cytochrome P450 2A6 deletion polymorphism and risk of lung cancer: a meta-analysis.Molecular biology reports · 2013Pooled it
- Pooled it
- Clinicopathological correlations of perineural invasion in resected non-small cell lung cancer.Frontiers in cell and developmental biology · 2026Article
- Efficacy of adjuvant tegafur-uracil (UFT) in early-stage non-small cell lung cancer with poor prognostic factors.Translational lung cancer research · 2025Article
- Histologic grade and STAS as key predictors of distant recurrence in resected early-stage lung adenocarcinoma: a single-center study.Frontiers in oncology · 2025Article
- Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review.Translational lung cancer research · 2024Review
- Lipid biomarkers that reflect postoperative recurrence risk in lung cancer patients who smoke: a case-control study.Lipids in health and disease · 2023Article
- Clinical Significance of Lymphatic Infiltration Detected by Immunohistochemical Double Staining in Patients with Endometrial Cancer.Clinical Medicine Insights. Oncology · 2023Article
- Combined measurement of circulating tumor cell counts and serum tumor marker levels enhances the screening efficiency for malignant versus benign pulmonary nodules.Thoracic cancer · 2022Article
- Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.BMC cancer · 2022Article
- Updated Prognostic Factors in Localized NSCLC.Cancers · 2022Review
- Impact of microvascular invasion on 5-year overall survival of resected non-small cell lung cancer.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2022Observational
- Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer.Thoracic cancer · 2020Article
- Sphingomyelin(d35:1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study.BMC cancer · 2020Observational
- Prognostic markers in resected large cell neuroendocrine carcinoma: a multicentre retrospective analysis.Journal of thoracic disease · 2020Article
- Article
- Lymphangiogenesis, lymphatic systemomics, and cancer: context, advances and unanswered questions.Clinical & experimental metastasis · 2018Review
- HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.Lung cancer (Amsterdam, Netherlands) · 2018Article
- Microvessel prediction in H&E Stained Pathology Images using fully convolutional neural networks.BMC bioinformatics · 2018Article
- Prognostic and predictive biomarkers post curative intent therapy.Annals of translational medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveBlood vessel invasion plays a very important role in the progression and metastasis of cancer. However, blood vessel invasion as a prognostic factor for survival in non-small cell lung cancer (NSCLC) remains controversial. The aim of this study is to explore the relationship between blood vessel invasion and outcome in patients with NSCLC using meta-analysis.
methodsA meta-analysis of published studies was conducted to investigate the effects of blood vessel invasion on both relapse-free survival (RFS) and overall survival (OS) for patients with NSCLC. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to assess the strength of this association.
resultsA total of 16,535 patients from 52 eligible studies were included in the systematic review and meta-analysis. In total, blood vessel invasion was detected in 29.8% (median; range from 6.2% to 77.0%) of patients with NSCLC. The univariate and multivariate estimates for RFS were 3.28 (95% CI: 2.14-5.05; P<0.0001) and 3.98 (95% CI: 2.24-7.06; P<0.0001), respectively. For the analyses of blood vessel invasion and OS, the pooled HR estimate was 2.22 (95% CI: 1.93-2.56; P<0.0001) by univariate analysis and 1.90 (95% CI: 1.65-2.19; P<0.0001) by multivariate analysis. Furthermore, in stage I NSCLC patients, the meta-risk for recurrence (HR = 6.93, 95% CI: 4.23-11.37, P<0.0001) and death (HR = 2.15, 95% CI: 1.68-2.75; P<0.0001) remained highly significant by multivariate analysis.
conclusionsThis study shows that blood vessel invasion appears to be an independent negative prognosticator in surgically managed NSCLC. However, adequately designed large prospective studies and investigations are warranted to confirm the present findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.